NanoMedical Systems

NanoMedical Systems is a United States-based drug-delivery device company located in Austin, Texas. It develops novel drug-delivery devices built on its proprietary nStrada nanofluidics platform, which is designed for the sustained release of chronic therapies. The company's flagship concept, nStrada, is a subcutaneous implant that provides long-term, constant release of a wide range of drugs and biologics. The nStrada Drug Delivery Platform uses state-of-the-art semiconductor manufacturing methods and biocompatible materials. Its core feature is a tunable, high-density array of precision nanochannels that regulates the delivery of drug molecules from an internal reservoir. The system requires no power and no moving parts for long-term constant delivery. Dosing, duration, and shape are set independently, and the device provides constant drug release via a nanochip without the "burst effect" or "bolus effect" that can affect other implant approaches. According to the company, the platform can support long-term durations ranging from weeks to more than a year. Devices can be pre-loaded or loaded by a physician during an office procedure at implantation. The platform is described as suitable for a wide range of active pharmaceutical ingredients, including small molecules, peptides, and proteins, and for both high- and low-solubility compounds. Performance has been demonstrated in vitro and in vivo. The capsule size and shape can be tailored independently of dosing, and the company positions the technology within a "combination product" regulatory pathway. NanoMedical Systems presents nStrada as an improvement over polymer-based implants and depots, which the company says suffer from an initial burst release and can take multiple weeks to achieve steady-state concentrations. By relying on diffusion — passive or controlled — through its nanochannel array, the nStrada device is intended to reach steady-state drug concentrations within a few days and then maintain constant release for the duration of the implant. The company is privately held and, as of the available evidence, operates primarily in the United States.

NanoMedical Systems is a company based in Austin, Texas, in the United States. Public evidence about the company is centered on its proprietary nStrada nanofluidics drug-delivery platform rather than on a detailed corporate chronology. The company describes itself as developing novel drug-delivery devices for the sustained release of chronic therapies, using state-of-the-art semiconductor manufacturing methods and biocompatible materials. The central technology, the nStrada Drug Delivery Platform, is built around a tunable high-density array of precision nanochannels that regulates the delivery of drug molecules from an internal reservoir. The device is designed to require no power and no moving parts for long-term constant delivery. Dosing, duration, and shape are set independently, and the platform provides constant drug release via a nanochip without a "burst effect" or "bolus effect." The company states that long-term duration of weeks to more than a year is possible, and that devices can be pre-loaded or loaded by a physician during an office procedure at implantation. NanoMedical Systems positions the platform for a wide range of active pharmaceutical ingredients, including small molecules, peptides, and proteins, with both high and low solubility. It reports demonstrated performance in vitro and in vivo, notes that capsule size and shape can be tailored independently of dosing, and places the technology within a "combination product" regulatory pathway. The company contrasts its approach with polymer-based implants and depots, which it says suffer from an initial burst release and take multiple weeks to achieve steady-state concentrations; by contrast, the nStrada devices rely on diffusion (passive or controlled) to achieve steady-state drug concentrations within a few days and then maintain constant release for the duration of the implant. Beyond these technology and positioning details, the available evidence does not provide a dated corporate history, founding year, founder names, ownership structure, or funding events. The company is identified as a company in Austin, United States, and appears to be privately held and active.

Developer of a proprietary nanofluidics-based subcutaneous implant platform for long-term, constant release of chronic therapies, positioned as an improvement over polymer-based implants and depots.

• nStrada Drug Delivery Platform

  A subcutaneous implant platform using a tunable high-density array of precision nanochannels to regulate drug release from an internal reservoir, requiring no power or moving parts for long-term constant delivery.

• nStrada subcutaneous implant

  An implant that provides long-term, constant release of a wide range of drugs and biologics, with dosing, duration, and shape set independently.

1. 1NanoMedical Systemsnanomedsys.com
2. 2NanoMedical Systems (United States)wikidata.org